Differential macrophage expression of IL-12 and IL-23 upon innate immune activation defines rat autoimmune susceptibility.
Rodents typically demonstrate strain-specific susceptibilities to induced autoimmune models such as experimental arthritis and encephalomyelitis. A common feature of the local pathology of these diseases is an extensive infiltration of activated macrophages (MPhi). Different functional activation states can be induced in MPhi during innate immune activation, and it is this differential activation that might be important in susceptibility/resistance to induction or perpetuation of autoimmunity. In this study, we present an extensive, comparative analysis of the activation phenotypes of MPhi derived from autoimmune-susceptible and autoimmune-resistant rat strains to describe a cellular phenotype that defines the disease phenotype. We included investigation of receptor function, intracellular signaling pathways, cytokines, and other soluble mediators released after activation of cells using a panel of stimuli embracing many activation routes. We report that activation of MPhi from the autoimmune-susceptible strain was associated with alternative activation indicated by induction of arginase activity, a lower production of classical proinflammatory mediators, and a high production of interleukin (IL)-23, and MPhi from the autoimmune-resistant strains were associated with a higher production of proinflammatory mediators, a classical activation phenotype, and preferential induction of IL-12. These MPhi phenotypes thus reflect disparate, genetic cellular programs that define autoimmune susceptibility.
Andersson
Asa
A
Department of Clinical Neurosciences, CMM L8:04, Karolinska Sjukhuset, S-171 76 Stockholm, Sweden. Asa.Andersson@cmm.ki.se
Kokkola
Riikka
R
Wefer
Judit
J
Erlandsson-Harris
Helena
H
Harris
Robert A
RA
D000818:Animals; D001119:Arginase / Q000276:immunology; D001327:Autoimmune Diseases / Q000235:genetics / Q000276:immunology*; D049109:Cell Proliferation; D002478:Cells, Cultured; D002634:Chemotaxis, Leukocyte / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D004195:Disease Models, Animal; D004789:Enzyme Activation / Q000276:immunology; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D007113:Immunity, Innate / Q000235:genetics / Q000276:immunology*; D018664:Interleukin-12 / Q000096:biosynthesis / Q000276:immunology*; D053759:Interleukin-23; D053760:Interleukin-23 Subunit p19; D007378:Interleukins / Q000096:biosynthesis / Q000276:immunology*; D020935:MAP Kinase Signaling System / Q000235:genetics / Q000276:immunology; D008264:Macrophages / Q000276:immunology* / Q000378:metabolism; D010641:Phenotype; D051381:Rats; D018121:Receptors, Cytokine / Q000276:immunology; D015398:Signal Transduction / Q000235:genetics / Q000276:immunology; D013045:Species Specificity
D016207:Cytokines; C508842:Il23a protein, rat; D053759:Interleukin-23; D053760:Interleukin-23 Subunit p19; D007378:Interleukins; D018121:Receptors, Cytokine; D018664:Interleukin-12; D001119:Arginase